How to buy Adaptive Biotechnologies Corporation stock | 10 March price $43.34

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Adaptive Biotechnologies Corporation stock in Canada | $43.34

Own Adaptive Biotechnologies Corporation shares in just a few minutes.

Adaptive Biotechnologies Corporation is a biotechnology business based in the US. Adaptive Biotechnologies Corporation shares (ADPT.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $43.34 – an increase of 2.63% over the previous week. Adaptive Biotechnologies Corporation employs 622 staff and has a trailing 12-month revenue of around $98.4 million.

How to buy shares in Adaptive Biotechnologies Corporation

  1. Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: ADPT in this case.
  5. Research Adaptive Biotechnologies Corporation shares. The platform should provide the latest information available.
  6. Buy your Adaptive Biotechnologies Corporation shares. It's that simple.

How has Coronavirus impacted Adaptive Biotechnologies Corporation's share price?

Since the stock market crash in March caused by coronavirus, Adaptive Biotechnologies Corporation's share price has had significant positive movement.

Its last market close was $43.34, which is 21.18% up on its pre-crash value of $34.16 and 185.32% up on the lowest point reached during the March crash when the shares fell as low as $15.19.

If you had bought $1,000 worth of Adaptive Biotechnologies Corporation shares at the start of February 2020, those shares would have been worth $755.26 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,444.52.

Adaptive Biotechnologies Corporation share price

Use our graph to track the performance of ADPT stocks over time.

Adaptive Biotechnologies Corporation shares at a glance

Information last updated 2021-04-14.
Latest market close$43.34
52-week range$27.28 - $71.25
50-day moving average $44.028
200-day moving average $52.0431
Wall St. target price$64.8
PE ratio 43.9569
Dividend yield N/A (0%)
Earnings per share (TTM) $-4.344

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Available asset types Stock Fee Option Fee Account Fee ETF Transaction Cost Feature Table description
Questrade
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$4.95-$9.95
$9.95 + $1 per contract
$0
Free
$0 account fee and free ETF transactions.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
$0 (if monthly commissions are greater than or equal to US$10.00)
Min. $1.00, Max. 0.5% of trade value
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Wealthsimple Trade
Stocks, ETFs
$0
N/A
$0
Free
Deposit and trade $100 and get a $25 bonus.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
Qtrade Investor
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$6.95 - $8.75 + $1.25 per contract
$0 if conditions met, otherwise $25/quarter
$0 - $8.75
Trade 100 ETFs free of charge.
Qtrade Investor offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.
Scotia iTRADE
Options, Mutual Funds, ETFs, GICs, International Equities
$4.99-$9.99
$9.99 + $1.25 contract ($4.99 + $1.25 contract if completed 150 trades or more a quarter)
$0
$9.99 ($4.99 if completed 150 trades or more a quarter)
Pay no annual account fees.
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy Adaptive Biotechnologies Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Adaptive Biotechnologies Corporation price performance over time

Historical closes compared with the last close of $43.34

1 week (2021-04-15) 0.72%
1 month (2021-03-22) 1.03%
3 months (2021-01-22) -36.02%
6 months (2020-10-22) -7.65%
1 year (2020-04-22) 43.04%

Is Adaptive Biotechnologies Corporation under- or over-valued?

Valuing Adaptive Biotechnologies Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Adaptive Biotechnologies Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Adaptive Biotechnologies Corporation's P/E ratio

Adaptive Biotechnologies Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 44x. In other words, Adaptive Biotechnologies Corporation shares trade at around 44x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Adaptive Biotechnologies Corporation financials

Revenue TTM USD$98.4 million
Gross profit TTM USD$-40,220,000
Return on assets TTM -9.42%
Return on equity TTM -22.25%
Profit margin -148.63%
Book value $5.4
Market capitalisation USD$6.2 billion

TTM: trailing 12 months

How to short and sell Adaptive Biotechnologies Corporation shares

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "ADPT.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 4.3 million Adaptive Biotechnologies Corporation shares held short by investors – that's known as Adaptive Biotechnologies Corporation's "short interest". This figure is 13.1% up from 3.8 million last month.

There are a few different ways that this level of interest in shorting Adaptive Biotechnologies Corporation shares can be evaluated.

Adaptive Biotechnologies Corporation's "short interest ratio" (SIR)

Adaptive Biotechnologies Corporation's "short interest ratio" (SIR) is the quantity of Adaptive Biotechnologies Corporation shares currently shorted divided by the average quantity of Adaptive Biotechnologies Corporation shares traded daily (recently around 1.5 million). Adaptive Biotechnologies Corporation's SIR currently stands at 2.92. In other words for every 100,000 Adaptive Biotechnologies Corporation shares traded daily on the market, roughly 2920 shares are currently held short.

However Adaptive Biotechnologies Corporation's short interest can also be evaluated against the total number of Adaptive Biotechnologies Corporation shares, or, against the total number of tradable Adaptive Biotechnologies Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Adaptive Biotechnologies Corporation's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Adaptive Biotechnologies Corporation shares in existence, roughly 30 shares are currently held short) or 0.0516% of the tradable shares (for every 100,000 tradable Adaptive Biotechnologies Corporation shares, roughly 52 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Adaptive Biotechnologies Corporation.

Find out more about how you can short Adaptive Biotechnologies Corporation stock.

Adaptive Biotechnologies Corporation share dividends

We're not expecting Adaptive Biotechnologies Corporation to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.

Adaptive Biotechnologies Corporation overview

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery customers. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site